Eurobank to distribute interim dividend after strong first half
The bank reported adjusted net earnings for the January-June period of 711 million euros ($812.96 million), slightly down from a record profit of 732 million euros a year earlier.
Chief Executive Fokion Karavias told analysts on a call that profit was "progressing according to our expectations".
"For the full year 2025 we have been committed to at least a 50% payout ratio... meaning that this may be higher than 50%," Karavias said, pointing to stronger than expected loan growth.
Greek banks are returning to profit after they were nationalised following a financial meltdown in late 2009 amid the country's debt crisis, requiring several capital injections from the government. They were fully privatised last year.
The European Central Bank (ECB) has approved requests by Greece's four largest lenders to resume dividend payments for 2024 after 16 years, a further sign of the sector's recovery and the country's economic rebound.
Eurobank, which also operates in Bulgaria and Cyprus, said in a statement that its net interest income rose 12% year-on-year to 1.27 billion euros while its non-performing loan exposure (NPE) ratio fell to 2.8% from 3.1% a year earlier.
Net fees jumped 29% to 364 million euros, mainly boosted by network activities and its wealth management business.
($1 = 0.8746 euros)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
5 minutes ago
- Reuters
Cheniere Energy posts jump in quarterly profit, enters supply deal with Japan's JERA
Aug 7 (Reuters) - Cheniere Energy (LNG.N), opens new tab on Thursday reported a second-quarter profit that nearly doubled, driven by steady demand for liquefied natural gas (LNG) and robust margins, and said it has signed a LNG supply deal with Japan's biggest power generator. The U.S. is the world's largest exporter of the superchilled gas and commercial activity has gained further momentum after President Donald Trump lifted a moratorium on new LNG export permits after taking office in January. In July, the European Union pledged $750 billion worth in strategic LNG purchases over three years from the U.S. as part of a sweeping trade pact, opening up opportunities for major producers like Cheniere. The company's LNG revenue was at $4.52 billion in the reported quarter, up about 43% from a year earlier, while the number of LNG cargoes exported was at 154, down by one, dragged down by maintenance activities. Separately, Cheniere and Japan's JERA signed a LNG supply agreement, under which JERA will purchase about 1 million tonne per annum of the superchilled gas from Cheniere from 2029 through 2050. In June, JERA agreed to new supply deals for U.S. liquefied natural gas to diversify its global portfolio away from its reliance on Australia. Cheniere also reported an adjusted core profit of $1.42 billion, missing analysts' average estimate of $1.56 billion, according to data compiled by LSEG. However, the company raised the lower end of its current- year adjusted core profit forecast by $100 million to between $6.6 billion and $7.0 billion. Cheniere's Corpus Christi Stage 3 project, an export facility in South Texas, was 86.7% complete as of June 30. The Stage 3 project is expected to add 10 million metric tons per annum (mtpa) of LNG to Cheniere's production capacity of 15 mtpa at the export facility. The company reported net income attributable to Cheniere of $1.63 billion, or $7.30 per share, for the quarter ended June 30, up nearly 85% from a year ago.
Telegraph
5 minutes ago
- Telegraph
The Government cannot take credit for cuts in interest rates
The Bank of England's decision to trim its key interest rate by another quarter point this week was widely expected, but there is still plenty to write about. Unfortunately, little of this is good news. For a start, why on earth is the Monetary Policy Committee (MPC) still cutting rates when the Bank itself now expects CPI inflation to rise further, peaking at 4 per cent in September? This would be double the MPC's 2 per cent target, which is meant to be met 'at all times'. That is a reasonable question. Indeed, the MPC only voted in favour by the slimmest of margins, with four of the nine members preferring to leave interest rates on hold. Fortunately, the MPC's mandate provides some flexibility. The mandate allows the target to be overshot temporarily if there are good reasons to expect inflation to drop back to target soon, and if the costs of correcting the overshoot more quickly – in terms of lost output and jobs – would otherwise be too great. The recent pick-up in inflation partly reflects global factors which are outside the Bank's control. These include the impacts of higher prices for energy and agricultural commodities, which should drop out of the headline inflation rate next year. Nonetheless, the gap between inflation in the UK and the rest of Europe has widened noticeably since last October's Budget. Despite the same global pressures, inflation in the euro area has settled at around 2 per cent. The obvious culprit is the continued pass through of higher payroll costs following the large increases in employers' National Insurance contributions and in minimum wages. It was always likely that these policy choices would backfire on 'working people', both by raising prices and hitting jobs. But they have made the MPC's task much more difficult too. Despite this, there are certainly some good reasons to expect the jump in inflation (excluding food and energy) to be temporary. The labour market is now cooling rapidly, meaning the risk of further wage-led inflation is much lower. Moreover, unlike in the post-Covid period when inflation was much stickier than most had expected, the money supply is now under control. This is partly due to the MPC's decision to keep monetary policy tight by selling government bonds, reversing the previous policy of 'quantitative easing'. Though few will pay much notice, the Bank's preferred measure of broad money (known as M4) is growing at an annualised rate of just 3 per cent. That is unlikely to be enough to sustain inflation much above 2 per cent, unless the UK economy is heading for a prolonged slump. Alas, the risks to economic activity are skewed to the downside. The immediate threat of a devastating global trade war has faded, but US tariffs will still be substantially higher than a year ago. At home, business and consumer confidence are already stuttering again as another punitive Budget looms in the Autumn. This has two implications. First, it makes perfect sense to return interest rates towards a more neutral level, rather than keep them higher to cap a rise in inflation that is likely to be temporary. Even at the new level of 4 per cent, interest rates are (just about) restrictive enough to continue bearing down on inflation, especially with the Bank also persisting with 'quantitative tightening'. The financial markets still expect the MPC to be forced to ease further, with rates bottoming out at around 3.5 per cent next year. Second, though, the Government cannot take any credit for the Bank of England's decision. The MPC has now delivered five interest rate cuts since last July's election. But the European Central Bank (ECB) has cut its key interest rate seven times over the same period – to just 2 per cent, and eight in total since the peak. The bottom line is that UK interest rates are still higher than they would have been if UK inflation were not such an outlier. They have only been cut at all because the tiniest majority of MPC members agreed that recession fears should trump the reality of rising inflation. This is not much to cheer.
Reuters
5 minutes ago
- Reuters
Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints
Aug 7 (Reuters) - Shares in Novo Nordisk ( opens new tab rose as much as 14% on Thursday after trial data from Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-leading obesity treatment. The company later pared some gains and were trading up 9% at 1240GMT. The market had anticipated Eli Lilly's orforglipron pill to become a strong competitor to Novo's weight-loss drugs, Kepler Cheuvreux analyst David Evans said in an emailed comment. However, with Thursday's results falling short of those expectations, Evans said investors were likely to rethink the competitive outlook in the GLP-1 obesity drug market, a shift that favours Novo's oral semaglutide. Eli Lilly shares were down 7.8% premarket at 1152 GMT. The battle between injectables and oral GLP-1 drugs is shaping obesity treatments, as companies race to deliver the best mix of results and safety for patients. Novo's shares plunged last week after it slashed its outlook for 2025 sales growth, marking the second forecast cut for the Danish drugmaker this year. Lilly's weaker pill data helps restore investor confidence in Novo's obesity lead, easing fears of an imminent threat to Wegovy's dominance and pricing power, Nordnet analyst Per Hansen has said. Novo's domestic peer Zealand Pharma ( opens new tab rose around 7% in afternoon trade. Shares in Germany's Gerresheimer ( opens new tab, maker of injector pens for Wegovy and Zepbound, also rose around 3%, as weaker oral pill data points to sustained demand for injectable obesity treatments. Up to the previous session's close, Novo and Zealand shares had lost more than half their value since the start of the year.
